The pharmacokinetics of 1-β-d-arabinofuranosylcytosine (ara-C) in humans following rapid i.v. administration and slow i.v. infusion is reported, as is a high-pressure liquid chromatographic method for ara-C determination in biological fluids. Plasma concentrations of ara-C following a single i.v. dose of 100 mg had a biphasic decline with a mean terminal half-life of 2.62 hr. The half-life following a 4- to 5-day infusion was 2.47 hr. ara-C is rapidly deaminated to 1-β-d-arabinofuranosyluracil. The ratio of ara-C to 1-β-d-arabinofuranosyluracil excreted in urine in 48 hr was 1:4 after infusion and 1:6 after rapid injection. Most of the ara-C was excreted with in 5 hr. Total drug and metabolite excretion was 70% in 48 hr. ara-C infusion was administered according to a Southwest Oncology Group treatment protocol in which the loading dose was one-fourth of the infusion dose over 4 hr. With this treatment schedule, minimum steady-state plasma concentrations were not achieved in most patients by 4 hr. In order to reach plasma concentrations rapidly, a schedule of a loading dose 3 times the hourly infusion rate is suggested.


Supported in part by Contract NCI-C-71-2184 and grants GM 15956 and CA 12644 from the USPHS.

This content is only available via PDF.